{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["NHLBI"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA498560"],"scientific_name":["Homo sapiens"],"long_description":["BADGER is a 56-week randomized, double-blind, three-treatment, three-period cross-over trial that will evaluate the differential improvement in control that is achieved following three separate treatment interventions in children whose asthma is not acceptably controlled on a low dose of ICS (per NAEPP guidelines). All participants will enter an 8-week run-in period during which time they will receive a dose of 1x ICS (fluticasone 200 ug/day). During this 8-week time period, running 2-week averages to establish the lack of acceptable asthma control will be calculated. Thus, a child could qualify for randomization at any time during this 8-week run-in period. This approach should maximize both patient safety and successful enrollment. Children will continue to receive 1x ICS during the... (for more see dbGaP study page.)"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"NHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)","description":"NHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)","dates":{"last_updated":"2025-09-24","first_public":"2018-10-28"},"accession":"PRJNA498560","cross_references":{"taxon":["9606"]}}